vs
ANI PHARMACEUTICALS INC（ANIP）とGIBRALTAR INDUSTRIES, INC.（ROCK）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $225.0M、GIBRALTAR INDUSTRIES, INC.の約1.1倍）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 24.9%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $26.2M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs -12.3%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
ジブラルタル・インダストリーズ社は、特殊建築資材、インフラ関連製品、再生可能エネルギー向け製品の製造・販売を行う有力企業です。換気システム、屋根用付属品、太陽光発電設置架台、造園用品などを取り扱い、主に北米の住宅・商業建設、クリーンエネルギー市場向けにサービスを提供しています。
ANIP vs ROCK — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $225.0M |
| 純利益 | $27.5M | — |
| 粗利率 | — | 25.3% |
| 営業利益率 | 14.1% | 7.9% |
| 純利益率 | 11.1% | — |
| 売上前年比 | 29.6% | 24.9% |
| 純利益前年比 | 367.5% | — |
| EPS（希薄化後） | $1.14 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $225.0M | ||
| Q3 25 | $227.8M | $310.9M | ||
| Q2 25 | $211.4M | $309.5M | ||
| Q1 25 | $197.1M | $290.0M | ||
| Q4 24 | $190.6M | $180.1M | ||
| Q3 24 | $148.3M | $277.1M | ||
| Q2 24 | $138.0M | $273.6M | ||
| Q1 24 | $137.4M | $292.5M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-89.1M | ||
| Q2 25 | $8.5M | $26.0M | ||
| Q1 25 | $15.7M | $21.1M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $34.0M | ||
| Q2 24 | $-2.3M | $32.2M | ||
| Q1 24 | $18.2M | $24.9M |
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 26.6% | ||
| Q2 25 | — | 28.4% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 29.0% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | — | 30.5% | ||
| Q1 24 | — | 28.9% |
| Q4 25 | 14.1% | 7.9% | ||
| Q3 25 | 15.9% | 12.8% | ||
| Q2 25 | 6.6% | 12.8% | ||
| Q1 25 | 13.3% | 8.8% | ||
| Q4 24 | -2.3% | 13.3% | ||
| Q3 24 | -13.8% | 15.6% | ||
| Q2 24 | 3.7% | 14.9% | ||
| Q1 24 | 14.8% | 10.8% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -28.6% | ||
| Q2 25 | 4.0% | 8.4% | ||
| Q1 25 | 8.0% | 7.3% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 12.3% | ||
| Q2 24 | -1.7% | 11.8% | ||
| Q1 24 | 13.2% | 8.5% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $-2.98 | ||
| Q2 25 | $0.36 | $0.87 | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $1.11 | ||
| Q2 24 | $-0.14 | $1.05 | ||
| Q1 24 | $0.82 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $115.7M |
| 総負債低いほど良い | — | $0 |
| 株主資本純資産 | $540.7M | $950.4M |
| 総資産 | $1.4B | $1.4B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $115.7M | ||
| Q3 25 | $262.6M | $89.4M | ||
| Q2 25 | $217.8M | $43.3M | ||
| Q1 25 | $149.8M | $25.1M | ||
| Q4 24 | $144.9M | $269.5M | ||
| Q3 24 | $145.0M | $228.9M | ||
| Q2 24 | $240.1M | $179.1M | ||
| Q1 24 | $228.6M | $146.7M |
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $540.7M | $950.4M | ||
| Q3 25 | $505.8M | $951.8M | ||
| Q2 25 | $436.8M | $1.0B | ||
| Q1 25 | $418.6M | $1.0B | ||
| Q4 24 | $403.7M | $1.0B | ||
| Q3 24 | $405.9M | $1.0B | ||
| Q2 24 | $455.8M | $975.7M | ||
| Q1 24 | $452.0M | $940.2M |
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.3B | $1.4B | ||
| Q3 24 | $1.3B | $1.4B | ||
| Q2 24 | $920.8M | $1.4B | ||
| Q1 24 | $914.5M | $1.3B |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $35.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $26.2M |
| FCFマージンFCF / 売上 | 11.8% | 11.7% |
| 設備投資強度設備投資 / 売上 | 0.5% | 4.1% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | — |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $120.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $35.5M | ||
| Q3 25 | $44.1M | $73.0M | ||
| Q2 25 | $75.8M | $44.9M | ||
| Q1 25 | $35.0M | $13.7M | ||
| Q4 24 | $15.9M | $19.9M | ||
| Q3 24 | $12.5M | $64.7M | ||
| Q2 24 | $17.4M | $36.5M | ||
| Q1 24 | $18.3M | $53.2M |
| Q4 25 | $29.1M | $26.2M | ||
| Q3 25 | $38.0M | $64.8M | ||
| Q2 25 | $71.8M | $27.3M | ||
| Q1 25 | $32.5M | $2.3M | ||
| Q4 24 | $13.5M | $14.1M | ||
| Q3 24 | $7.7M | $60.5M | ||
| Q2 24 | $13.0M | $33.5M | ||
| Q1 24 | $13.7M | $48.8M |
| Q4 25 | 11.8% | 11.7% | ||
| Q3 25 | 16.7% | 20.8% | ||
| Q2 25 | 34.0% | 8.8% | ||
| Q1 25 | 16.5% | 0.8% | ||
| Q4 24 | 7.1% | 7.8% | ||
| Q3 24 | 5.2% | 21.8% | ||
| Q2 24 | 9.4% | 12.2% | ||
| Q1 24 | 10.0% | 16.7% |
| Q4 25 | 0.5% | 4.1% | ||
| Q3 25 | 2.7% | 2.6% | ||
| Q2 25 | 1.9% | 5.7% | ||
| Q1 25 | 1.3% | 3.9% | ||
| Q4 24 | 1.3% | 3.3% | ||
| Q3 24 | 3.2% | 1.5% | ||
| Q2 24 | 3.2% | 1.1% | ||
| Q1 24 | 3.3% | 1.5% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 1.73× | ||
| Q1 25 | 2.23× | 0.65× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.13× | ||
| Q1 24 | 1.00× | 2.13× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
